Pharmacokinetics of the angiotensin receptor-neprilysin inhibitor LCZ696 in furosemide-treated dogs

被引：0
|
作者：
Mochel, J. [1 ]
Seewald, W. [2 ]
Danhof, M. [3 ]
机构：
[1] Novartis Pharmaceut, Integrated Quantitat Sci, Basel, Switzerland
[2] Novartis, Elanco Anim Hlth, Dept Res & Dev, Basel, Switzerland
[3] Leiden Acad Ctr Drug Res, Dept Pharmacol, Leiden, Netherlands
来源：
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS | 2015年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
15.2
引用
收藏
页码：44 / 45
页数：2
相关论文
共 50 条
  • [21] LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Increases Nitric Oxide Bioavailability and Improves Vascular Function in Ischemic Heart Failure
    Trivedi, Rishi K.
    Li, Zhen
    Polhemus, David J.
    Yoo, Daniel
    Koiwaya, Hiroshi
    Goodchild, Traci T.
    Lefer, David J.
    CIRCULATION, 2017, 136
  • [22] First-in-class angiotensin receptor-neprilysin inhibitor LCZ696 markedly influences the dynamics of circulating cGMP and biomarkers of the renin-angiotensin aldosterone system in dogs
    Mochel, J.
    Peyrou, M.
    Giraudel, J.
    Danhof, M.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2015, 38 : 17 - 17
  • [23] Efficacy of LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in obese and overweight subjects with hypertension
    Ruilope, L. M.
    Izzo, J. L., Jr.
    Conde, L. G.
    Zappe, D. H.
    Zhang, Y.
    Zhang, J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 65 - 65
  • [24] Treatment with LCZ696, an Orally Active Angiotensin Receptor Neprilysin Inhibitor Prevents Ischemic Brain Damage
    Bai, Hui-Yu
    Mogi, Masaki
    Nakaoka, Hirotomo
    Kan-no, Harumi
    Tsukuda, Kana
    Chisaka, Toshiyuki
    Wang, Xiao-Li
    Kukida, Masayoshi
    Shan, Bao-Shuai
    Iwanami, Jun
    Horiuchi, Masatsugu
    HYPERTENSION, 2014, 64
  • [25] LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
    Martin P Lefkowitz
    BMC Pharmacology and Toxicology, 16 (Suppl 1)
  • [26] LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice
    Ge, Qing
    Zhao, Li
    Liu, Chen
    Ren, Xiaoming
    Yu, Yi-hui
    Pan, Chang
    Hu, Zuoying
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [27] Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor
    Ushijima, Kentaro
    Ando, Hitoshi
    Arakawa, Yusuke
    Aizawa, Kenichi
    Suzuki, Chisato
    Shimada, Ken
    Tsuruoka, Shu-ichi
    Fujimura, Akio
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2017, 5 (04):
  • [28] Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
    Voors, Adriaan A.
    Gori, Mauro
    Liu, Licette C. Y.
    Claggett, Brian
    Zile, Michael R.
    Pieske, Burkert
    McMurray, John J. V.
    Packer, Milton
    Shi, Victor
    Lefkowitz, Martin P.
    Solomon, Scott D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (05) : 510 - 517
  • [29] Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension
    Kario, Kazuomi
    Sun, Ningling
    Chiang, Fu-Tien
    Supasyndh, Ouppatham
    Baek, Sang Hong
    Inubushi-Molessa, Akiko
    Zhang, Ying
    Gotou, Hiromi
    Lefkowitz, Martin
    Zhang, Jack
    HYPERTENSION, 2014, 63 (04) : 698 - 705
  • [30] LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone
    Kusaka, Hiroaki
    Sueta, Daisuke
    Koibuchi, Nobutaka
    Hasegawa, Yu
    Nakagawa, Takashi
    Lin, BoWen
    Ogawa, Hisao
    Kim-Mitsuyama, Shokei
    AMERICAN JOURNAL OF HYPERTENSION, 2015, 28 (12) : 1409 - 1417
12345